Skip to main content

Table 5 Statistical analysis of patient characteristics of RFS data

From: The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010

  Univariate analysis Multivariate analysis
p–value HR [95%CI] p–value HR [95%CI]
Age 0.007 1.011 [1.003–1.019] 0.006 1.012 [1.004–1.021]
Gender (female vs. male)  < 0.001 0.632 [0.550–0.726] 0.038 0.806 [0.657–0.988]
Smoking history (+ vs. –)  < 0.001 1.519 [1.319–1.748] 0.552 0.938 [0.761–1.157]
Operation time  < 0.001 1.003 [1.002–1.004]  < 0.001 1.002 [1.001–1.003]
Invasion
  Lymphatic vessel invasion (+ vs. –)  < 0.001 3.123 [2.706–3.605] 0.002 1.330 [1.113–1.590]
  Vascular invasion (+ vs. –)  < 0.001 3.206 [2.779–3.698]  < 0.001 1.377 [1.155–1.643]
  Pleural invasion (+ vs. –)  < 0.001 2.574 [2.243–2.954] 0.448 1.070 [0.899–1.274]
Adenocarcinoma predominance
AIS + MIA   control   control
Lepidic 0.01 1.694 [1.132 – 2.533] 0.678 1.100 [0.702 – 1.722]
Acinar + Papillary + Variants  < 0.001 3.952 [2.783–5.611] 0.012 1.686 [1.124 – 2.530]
Solid + Micropapillary  < 0.001 7.041 [4.820–10.285]  < 0.001 2.221 [1.421—3.472]
EGFR status (+ vs. –) 0.205 0.902 [0.768–1.058]   
Adjuvant chemotherapy (+ vs. –)  < 0.001 0.481[0.420—0.537] 0.016 0.812 [0.686—0.962]
Clinical stage
  Stage IA   control   control
  Stage IB  < 0.001 1.802 [1.535—2.115] 0.332 1.099 [0.908—1.329]
  Stage IIA  < 0.001 3.097 [2.481—3.866] 0.19 1.191 [0.917—1.546]
  Stage IIB  < 0.001 3.916 [2.913—5.266] 0.024 1.500 [1.055—2.135]
  Stage IIIA  < 0.001 5.774 [4.505—7.401] 0.017 1.454 [1.069—1.978]
Pathological stage
  Stage IA   control   control
  Stage IB  < 0.001 2.556 [2.097—3.116]  < 0.001 1.888 [1.459—2.442]
  Stage IIA  < 0.001 5.767 [4.621—7.197]  < 0.001 3.482 [2.613—4.640]
  Stage IIB  < 0.001 7.042 [5.316—9.328]  < 0.001 3.953 [2.737—5.710]
  Stage IIIA  < 0.001 10.288 [8.462—12.508  < 0.001 5.681 [4.247—7.600]